drug_type
RELEVANT_DRUG
intervention_type
cell therapy
drug_description
Autologous CD8+/CD4+ T cells expanded ex vivo from the patient's tumor to recognize tumor antigens via native TCRs; administered as adoptive cell therapy.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Lymphocytes, Tumor-Infiltrating
drug_category
TUMOR INFILTRATING LYMPHOCYTES
drug_class
Unedited cells
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous tumor-infiltrating CD8+/CD4+ T cells expanded ex vivo are reinfused to restore large numbers of tumor-reactive lymphocytes. Using native TCRs, they recognize patient-specific tumor antigens presented on MHC, traffic to tumor sites, and mediate cytotoxicity via perforin/granzyme release and cytokine secretion. Lymphodepletion and IL-2 support enhance in vivo expansion and persistence.
drug_name
Tumor-Infiltrating Lymphocytes (TIL)
nct_id_drug_ref
NCT06532799